Haleon plc (HLN) Stock Price & Analysis
Haleon plc (HLN) — MoonshotScore 75/100 (Strong band), calculated Nov 18, 2026. Price $9.08 (+0.33%), as of the Nov 18, 2026 trading session; market cap $39.8B.
Educational signal · not a buy or sell recommendation · How to read this
Haleon plc · HLN · NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Haleon (HLN)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and durable growth, though the balance sheet is only middling; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Fair; Growth Durability: Growing; Momentum: Rising.
- quarterly revenue £5.64B (Q2 FY2026, quarter ended Jun 30, 2026)
- Altman Z 2.85 · Piotroski F 8
- ROE 9.9% · ROA 5.0% · current ratio 0.69 · earnings yield 5.2% · free-cash-flow yield 3.9%
Helping: business quality, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 75 | Strong | |
| 75 | Strong | |
| 75 | Strong | |
| 75 | Strong | |
| 75 | Strong | |
| 75 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $9.08 | |
| Change on the day | +0.33% | |
| 52-week range | $8.38–$11.28 | |
| Market capitalisation | $39.8B | — |
| Price / earnings (trailing) | 18.87 | |
| Shares traded on the day | 19.46M | |
| Beta (volatility vs the S&P 500) | 0.25 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Haleon (HLN): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Haleon (HLN), and what does it report?
Short answer
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. Haleon plc (HLN) is listed on NYSE. Healthcare / Drug Manufacturers Specialty & Generic SEC filing business address: Building 5, First Floor, THE Heights, Weybridge, X0, KT13 0NY. It employs 24,535 people and is led by Brian James McNamara. In Q2 FY2026 it reported revenue of £5.64B and net income of £768M. The market values it at $39.8B.
What do the latest results show for Haleon (HLN)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of £5.64B.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | £5.64B | £768M | £0.17 (diluted) |
| Q4 FY2025 | £5.52B | £856M | £0.19 (diluted) |
| Q2 FY2025 | £5.48B | £806M | £0.18 (diluted) |
| Q1 FY2025 | £2.74B | £403M | £0.09 (diluted) |
What are the financial strengths and risks for Haleon (HLN)?
Short answer · as of
The MoonshotScore pillars rate business quality, durable growth, positive momentum as strengths. The distress and quality screens read Altman Z 2.85 · Piotroski F 8. Trailing ratios: ROE 9.9% · ROA 5.0% · current ratio 0.69 · earnings yield 5.2% · free-cash-flow yield 3.9%.
How does Haleon compare with its peers?
Short answer
Haleon's score ranks 7th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $102.00 Nov 18, 2026 | $6.67B | 96 5-pillar Nov 18, 2026 | |
| $272.37 Nov 19, 2026 | $63.0B | 88 5-pillar Nov 18, 2026 | |
| $85.57 Nov 18, 2026 | $34.8B | 87 5-pillar Nov 18, 2026 | |
| $177.33 Nov 18, 2026 | $50.0B | 83 5-pillar Nov 18, 2026 | |
| $385.78 Nov 18, 2026 | $46.3B | 79 5-pillar Nov 18, 2026 | |
| $14.85 Nov 19, 2026 | $12.4B | 77 5-pillar Nov 18, 2026 | |
| Haleon (HLN) — this page | $9.08 | $39.8B | 75 |
| $28.96 Nov 18, 2026 | $6.02B | 74 5-pillar Nov 18, 2026 | |
| $21.27 Nov 18, 2026 | $68.0B | 73 5-pillar Nov 18, 2026 | |
| $13.99 Nov 18, 2026 | $2.43B | 70 5-pillar Nov 18, 2026 | |
| $212.73 Nov 19, 2026 | $57.9B | 68 5-pillar Nov 18, 2026 | |
| $21.88 Nov 18, 2026 | $7.62B | 66 5-pillar Nov 18, 2026 | |
| $42.23 Nov 18, 2026 | $49.3B | 57 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held HLN in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported HLN in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Haleon (HLN)?
HLN Healthcare Stock FAQ
These answers are editorial: 1 of these 9 answers is drawn from the HLN research dossier (written Jun 14, 2026 by gpt-4o-mini); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for HLN?
HLN carries the MoonshotScore stated above — the Strong band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Haleon plc (HLN) is a leading consumer healthcare company focused on the research, development, and sale of over-the-counter products.
Is HLN a good stock to buy?
Stock Expert AI does not rate HLN buy, sell or hold. Haleon plc carries a MoonshotScore, in the Strong band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the HLN stock price today?
The last price recorded for Haleon plc (HLN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for HLN?
Haleon plc faces several risks, including regulatory hurdles that could delay product approvals, impacting its ability to launch new products.
What are the key factors to evaluate for HLN?
Haleon plc (HLN) holds a MoonshotScore in the high range. To weigh it, start with the trailing P/E under Price & valuation on this page. Haleon's established brand presence and distribution networks will enable it to capture a larger market share in these regions over the next five years. Not financial advice.
How frequently does HLN data refresh on this page?
HLN's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven HLN's recent stock price performance?
Haleon plc (HLN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong brand portfolio with high consumer recognition. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HLN overvalued or undervalued right now?
The trailing P/E of Haleon plc (HLN) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research HLN before investing?
Before investing in Haleon plc (HLN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 19 figures on this page — 1 from SEC filings and earnings calls, 14 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
ETFs that hold HLN
Funds in our ETF coverage that list HLN among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| GMO International Quality ETF (QLTI) | 4.00% |